It also can lead to ulcers
From OWL833 to Orforglipron: The Clinical Development Arc Eli Lilly's clinical development of orforglipron proceeded rapidly following the 2018 licensing agreement
Sermorelin protocols vary based on hormone status, IGF-1 response, age, goals, and metabolic markers
doi: 10.3389/fpubh.2025.1566260 Received 17 February 2025 Accepted 30 May 2025 Published 03 September 2025 Volume 13 - 2025 Edited by Rawad Hodeify, American University of Ras Al Khaimah, United Arab Emirates Reviewed by Vibhuti Gupta, Meharry Medical College, United States Vijendra Ramlall, Memorial Sloan Kettering Cancer Center, United States Updates Copyright 2025 Xiong, Cai, Lai, Wang, Xin, Song, Lv, Guo, Yang and Wu